Ardelyx, Inc.

Amgen Inc.

Irina Dotsenko

Dean R Dragoli

Jason Gustaf Lewis

Pasit Phiasivongsa

Ge Peng

Gary W Luehr

Shabbir T Anik

Dante Romanini

Michael Robert Leadbetter

Jeffrey William Jacobs

Christopher Carreras

Noah Bell

Matthew John Siegel

Andrew King

Ying He

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

Compounds useful for treating gastrointestinal tract disorders

The present disclosure is directed to compounds (I') and to their use in methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds (I&#x2032;) and their use in methods for the treatment of hypertension. The present disclosure is also directed to compounds (I&#x2032;) and to their use in methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. 

Inhibitors of NHE-mediated antiport

The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R, R, linker, PEG, n and o are as defined herein.

Pegylated carfilzomib compounds

The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R, R, linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Growing community of inventors

San Jose, CA, United States of America

Irina Dotsenko